Dr. Sidransky is widely recognized as being among the Nation's leading oncologists as well as among the most influential authorities in the field of biotechnology. He currently serves as Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and is Professor of Oncology, Urology, Cellular & Molecular Medicine, Pathology, Otolaryngology and Genetics at Johns Hopkins University School of Medicine. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine.
He is a founder of several private biotechnology companies and has served on the scientific advisory boards of many noted private and public companies, including Medimmune, Roche, and Amgen. He is formerly a member of the Recombinant DNA Advisory Committee at the National Institute of Health and is currently the Vice Chairman of the Board of ImClone Systems.
"Dr. Sidransky has an extraordinary combination of unique medical expertise, practical business experience, and effective leadership skills," said Dr. L. David Tomei, CEO and Co-Founder of Xenomics. "To have an individual of David's stature joining our Board is powerful encouragement for our continuing efforts to provide physicians and patients a new generation of molecular diagnostic tests with the real potential to significantly improve health care for millions of people all over the world."
"Dr. Sidransky was one of the first researchers to describe the appearance of DNA fragments in the blood stream," commented Dr. Samuil Umansky, CSO of Xenomics. "Among our goals is to create diagnostic tests of DNA fragments in non-invasive urine specimens. Dr. Sidransky's contributions to our efforts will be invaluable."
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine specimens and is being applied to a broad range of applications including detection and monitoring of infectious diseases, tumor detection and therapeutic monitoring, stem cell transplantation monitoring, and prenatal genetic testing. Scientists from Xenomics were the first to discover that fragments of DNA from cells throughout the body can cross the kidney barrier and be readily detected in small urine specimens. The Company believes that its transrenal DNA technology will open significant new markets in the molecular diagnostics field and provide a new generation of molecular diagnostic tests. Xenomics' issued U.S. patents protect an array of applications for molecular diagnostics and genetic testing. The Company has been joined by the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive "Lazarus Spallanzani") in Rome, in formation of a research and development company called SpaXen Italia, S.R.L, where clinical researchers are focused on transrenal DNA diagnostics for a variety of infectious diseases. For additional information, please visit www.xenomics.com . Xenomics' stock trades under the symbol XNOM.OB and is also listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics' Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Contact: Xenomics, Inc. L. David Tomei 212-297-0808 ldtomei@xenomics.com
Source: Xenomics, Inc.
